Stirred Suspension Culture for Scalable Stem Cell Aggregates

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for scaling up stem cell cultures are inefficient in producing high-density stem cell aggregates, which are necessary for clinical applications, as they often disrupt cellular proliferation and growth, and do not effectively recapitulate in-vivo phenotypes.

Innovation Solution

The development of a method to cultivate stem cell aggregates in non-static conditions, such as stirred suspension, allowing for the expansion of aggregates from initial sizes of 10 cells to up to 50,000 cells with a maximum diameter of 1mm, achieving cell densities from 5x10^4 to 10^8 cells/ml in volumes ranging from 10ml to 20,000L, using non-adherent bioreactors like spinner flasks and mixing tank bioreactors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cell aggregates are cultured in static conditions, then aggregate formation is maintained, but cellular proliferation and growth are disrupted

Engineering Contradiction:
Improveaggregate formationVSAvoidcellular proliferation
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The invention transitions from static culture conditions to dynamic non-static conditions (stirred suspension culture). This dynamic approach allows aggregates to form and maintain their structure while enabling continuous cellular proliferation and growth, resolving the contradiction between reliable aggregate formation and productive cell proliferation.

Inventive Principle:
Principle #15Dynamics

2Ease of manufacture

If traditional 2D monolayer culture methods are used, then cell production is simplified, but in-vivo phenotype recapitulation is poor

Engineering Contradiction:
Improveculture simplicityVSAvoidin-vivo phenotype recapitulation
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The invention transitions from two-dimensional monolayer culture to three-dimensional aggregate culture in stirred suspension. This dimensional change enables better recapitulation of in-vivo phenotypes through improved cell-cell and cell-matrix interactions, while maintaining scalability for clinical production.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

3Quantity of substance

If stem cell cultures are scaled up for clinical applications, then cell density increases, but aggregate integrity and growth are compromised

Engineering Contradiction:
Improvecell densityVSAvoidaggregate integrity
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The stirred suspension culture system provides dynamic mixing that prevents aggregate aggregation and maintains uniform distribution, allowing scale-up to high cell densities (5x10^4 to 10^8 cells/ml) while preserving aggregate integrity and continued growth capability.

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the production of high-density stem cell cultures that maintain cellular proliferation and growth without disrupting aggregate formation, allowing for scalable and clinically relevant cell production while retaining the in-vivo phenotype, suitable for various applications including drug screening and tissue development.

Implementation Method 1

non-static conditions, such as stirred suspension

Methodology Applied
Scientific EffectStirring: Stirring

Implementation Method 2

cultivating them as aggregates or on microcarriers

Methodology Applied
Scientific EffectSuspension: Suspension

Data Source

PatentEP2609191B1Non-static suspension culture of cell aggregates
Publication Date: 2017.11.22 KATHOLIEKE UNIV LEUVEN
  • EP2609191B1 patent drawingFigure 1
  • EP2609191B1 patent drawingFigure 2
  • EP2609191B1 patent drawingFigure 3

AI summary

The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.